DE602005027883D1 - 2-o, 3-o desulfatiertes heparin zur behandlung von heparininduzierter thrombozytopenie (hit) - Google Patents

2-o, 3-o desulfatiertes heparin zur behandlung von heparininduzierter thrombozytopenie (hit)

Info

Publication number
DE602005027883D1
DE602005027883D1 DE602005027883T DE602005027883T DE602005027883D1 DE 602005027883 D1 DE602005027883 D1 DE 602005027883D1 DE 602005027883 T DE602005027883 T DE 602005027883T DE 602005027883 T DE602005027883 T DE 602005027883T DE 602005027883 D1 DE602005027883 D1 DE 602005027883D1
Authority
DE
Germany
Prior art keywords
desulfated heparin
heparin
medicament
thrombocytopeny
heparine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005027883T
Other languages
German (de)
English (en)
Inventor
Jeanine M Walenga
Thomas Preston Kennedy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ParinGenix Inc
Original Assignee
ParinGenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ParinGenix Inc filed Critical ParinGenix Inc
Publication of DE602005027883D1 publication Critical patent/DE602005027883D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/10—Heparin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
DE602005027883T 2004-10-27 2005-10-26 2-o, 3-o desulfatiertes heparin zur behandlung von heparininduzierter thrombozytopenie (hit) Expired - Lifetime DE602005027883D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/974,566 US7468358B2 (en) 2004-06-16 2004-10-27 Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome
PCT/US2005/039011 WO2006047755A2 (en) 2004-10-27 2005-10-26 Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (hit) syndrome

Publications (1)

Publication Number Publication Date
DE602005027883D1 true DE602005027883D1 (de) 2011-06-16

Family

ID=36228513

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005027883T Expired - Lifetime DE602005027883D1 (de) 2004-10-27 2005-10-26 2-o, 3-o desulfatiertes heparin zur behandlung von heparininduzierter thrombozytopenie (hit)

Country Status (9)

Country Link
US (1) US7468358B2 (https=)
EP (1) EP1807095B1 (https=)
JP (1) JP2008518090A (https=)
AT (1) ATE507836T1 (https=)
AU (1) AU2005299568A1 (https=)
CA (1) CA2585640C (https=)
DE (1) DE602005027883D1 (https=)
ES (1) ES2366342T3 (https=)
WO (1) WO2006047755A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261241A1 (en) * 2004-05-19 2005-11-24 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
CA2678587A1 (en) * 2007-02-28 2008-09-04 Paringenix, Inc. O-desulfated heparins treating acute exacerbations of chronic obstructive pulmonary disease
WO2009015183A1 (en) * 2007-07-23 2009-01-29 University Of Utah Research Foundation Method for blocking ligation of the receptor for advanced glycation end-products (rage)
WO2009117677A2 (en) * 2008-03-21 2009-09-24 University Of Utah Research Foundation Methods for controlling intracellular calcium levels associated with an ischemic event
CA2777099C (en) * 2009-07-31 2018-03-27 Reliable Biopharmaceutical Corporation Process for preparing fondaparinux sodium and intermediates useful in the synthesis thereof
US8420790B2 (en) 2009-10-30 2013-04-16 Reliable Biopharmaceutical Corporation Efficient and scalable process for the manufacture of Fondaparinux sodium
KR102082276B1 (ko) * 2010-09-14 2020-02-27 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 고순도 헤파린 및 그 제조방법
JP2014501730A (ja) * 2010-12-01 2014-01-23 ジ オーストラリアン ナショナル ユニバーシティ ヒストン阻害
WO2013016181A1 (en) * 2011-07-22 2013-01-31 Paringenix, Inc. Compositions and methods for anti-coagulation
EP2809678B1 (en) 2012-02-02 2017-03-22 Reliable Biopharmaceutical Corporation An efficient and scalable process for the manufacture of fondaparinux sodium
CN104411316B (zh) * 2012-05-09 2018-05-01 坎泰克斯制药股份有限公司 骨髓抑制的治疗
AU2016234916A1 (en) * 2012-05-09 2016-11-17 Cantex Pharmaceuticals, Inc. Treatment of myelosuppression
US20170096549A1 (en) 2014-03-17 2017-04-06 Cantex Pharmaceuticals, Inc. Multivalent cation formulations of partially desulfated heparins
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
CN107430137B (zh) * 2015-03-03 2020-11-20 美国控股实验室公司 用于测量样品中的血清素的方法和系统
EP3810125B1 (en) * 2018-06-03 2025-07-23 Glycomira Therapeutics, Inc. Sulfated polysaccharide for use in preventing oral mucositis after exposure to ionizing radiation
WO2022015794A1 (en) 2020-07-14 2022-01-20 Optimvia, Llc Methods for synthesizing non-anticoagulant heparan sulfate
GB202006960D0 (en) * 2020-05-12 2020-06-24 Aplagon Oy Therapeutic

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1164145E (pt) * 1992-07-24 2008-03-17 Paringenix Inc Heparinas dessulfatadas não anticoagulantes como medicamentos
US5668118A (en) * 1992-07-24 1997-09-16 Cavalier Pharmaceuticals Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G
US5696100A (en) * 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
US5990097A (en) * 1996-07-29 1999-11-23 Cavalier Pharmaceuticals Methods of treating asthma with o-desulfated heparin
CN1326355A (zh) * 1998-11-13 2001-12-12 伊莱利利公司 治疗肝素诱导的血小板减少症的方法
EP1223948A2 (en) 1999-09-13 2002-07-24 CHARLOTTE-MECKLENBURG HOSPITAL doing business as Carolinas Medical Center Method of inhibiting nf-kappa-b with heparin, for treating cardiovascular diseases and inflammations
US6489311B1 (en) * 2000-05-02 2002-12-03 Charlotte-Mecklenburg Hospital Authoirty Method for the prevention of apoptosis
WO2004050673A2 (en) 2002-11-27 2004-06-17 Massachusetts Institute Of Technology Methods for synthesizing polysaccharides
US20050261241A1 (en) * 2004-05-19 2005-11-24 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
US20050282775A1 (en) 2004-06-16 2005-12-22 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome

Also Published As

Publication number Publication date
EP1807095A4 (en) 2008-08-27
WO2006047755A3 (en) 2007-02-01
US20070123489A1 (en) 2007-05-31
EP1807095A2 (en) 2007-07-18
AU2005299568A1 (en) 2006-05-04
EP1807095B1 (en) 2011-05-04
ES2366342T3 (es) 2011-10-19
WO2006047755A2 (en) 2006-05-04
JP2008518090A (ja) 2008-05-29
ATE507836T1 (de) 2011-05-15
CA2585640C (en) 2012-01-10
US7468358B2 (en) 2008-12-23
CA2585640A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
DE602005027883D1 (de) 2-o, 3-o desulfatiertes heparin zur behandlung von heparininduzierter thrombozytopenie (hit)
Gray et al. The anticoagulant and antithrombotic mechanisms of heparin
Kidane et al. Anticoagulant and antiplatelet agents: their clinical and device application (s) together with usages to engineer surfaces
WO2006023397A3 (en) Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
ATE523212T1 (de) Synthetische mehrschichtige hornhautstrukturen mit kollagen-fasern
DE60333937D1 (de) Substituierte quinazolinone verbindungen
FR2648463B1 (fr) Polysaccharides sulfates, agent anticoagulant et agent anticomplementaire obtenus a partir de fucanes d'algues brunes et leur procede d'obtention
UA100378C2 (uk) Полімерна композиція, спосіб її виготовлення, виріб, спосіб його виготовлення та спосіб формування, застосування, спосіб підвищення швидкості текучості розплаву суміші та спосіб зменшення технологічного циклу формування виробу
BR8304973A (pt) Mistura de polimero compativel
MY149505A (en) Hyaluronic acid binary mixtures and therapeutic use thereof
NO983135L (no) Farmasaaytisk preparat
DE602006008985D1 (de) Zusammensetzung enthaltend oligosaccharide als lösliche ballaststoffe zur verwendung gegen muskelschwund
ES2296346T3 (es) Compuestos similares a la heparina, su preparacion y utilizacion para prevenir la trombosis arterial asociada a lesiones e intervenciones vasculares.
Patel Blood biocompatibility enhancement of biomaterials by heparin immobilization: a review
Wang et al. The effect of hirudin modification of silk fibroin on cell growth and antithrombogenicity
JP2008518090A5 (https=)
FR2866571B1 (fr) Utilisation d'un melange de polysaccharides specifiques denomme par l'inventeur ezbone, comprenant de l'acide hyaluronique, de la chondroitine 6 sulfate, du dermatane sulfate et de l'heparine en cicatrisation osseuse.
Lee et al. Improved calcification resistance and biocompatibility of tissue patch grafted with sulfonated PEO or heparin after glutaraldehyde fixation
ATE359798T1 (de) Verwendungvon dextransulfat zur behandlung von ibmir
BR112021010615A2 (pt) Clazakizumab no tratamento de rejeição crônica de transplante de órgãos mediada por anticorpos
EP1940439A4 (en) REDUCTION OF POSTOPERATIVE ADHESION FORMATION WITH INTRAPERITONEAL GLUTAMINE
IL165807A0 (en) Process for preparing epimerized derivatives of k5polysaccharide with a very high degree of sulfati on and new epi k5-n,o-sulfated polysaccharide derivatives
WO2001015654A3 (fr) Polysaccharide antithrombotique de bas poids moleculaire
Xue et al. PU/PTFE-stimulated monocyte-derived soluble factors induced inflammatory activation in endothelial cells
Richardson et al. Transient morphological and biochemical alterations of arterial proteoglycan during early wound healing